HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
Cardio 2022

Tripti Sharma

Tripti Sharma, Speaker at Cardiology Conferences
USV Pvt Ltd, India
Title : Clinical effectiveness of telmisartan as monotherapy for the management of Sri Lankan patients with hypertension


Background: There is an increase in number of hypertension patient in the Republic of Sri Lanka. Telmisartan is an angiotensin II receptor blocker & preferred as treatment of choice to achieve target blood pressure.

Objective: The present study was conducted to evaluate the clinical effectiveness of telmisartan as monotherapy for the management of hypertension in Sri Lanka.

Methods: This was a multicentric survey included patients with aged >18 years receiving telmisartan as monotherapy for the management of hypertension. Study was conducted between Nov 2020 and Jan 2021. Data was collected during each visit at baseline, day 45, and day 90, from selected clinics/ hospitals.

Results: A total of 264 patients with mean age of 59.3 years were part of this study where only 92 patients received telmisartan as monotherapy. Majority of patients were men (61.6%). The most prescribed dosage of telmisartan was 40 mg (70.6%) followed by 80 mg (17.5%) and 20 mg (11.9). Diabetes was observed in 60 (33.9%) patients with hypertension. A significant reduction in the SBP/DBP was observed during the course of telmisartan monotherapy (Figure 1). The mean (95% confidence interval) change in SBP and DBP from baseline to day 45 and day 90 was 10.7 (8.9-12.5); P<0.0001 and 6.2 (4.8-7.7); P<0.0001, 24.7 (21.9-27.4); P<0.0001 and 10.6 (9.2-12.1); P<0.0001, and 14.7 (12.7-16.8); P<0.0001 and 4.5 (3.2-5.9); P<0.0001, respectively.

Conclusion: A significant improvement in blood pressure was associated with telmisartan monotherapy and found to be effective in Sri Lankan patients with hypertension.

What will audience learn from your presentation?

  1. Telmisartan monotherapy is effective in maintaining clinically relevant reductions of both systolic & diastolic blood pressure.
  2. Telmisartan may be a good candidate for blood pressure control with comorbidities like diabetes during routine clinical practice.
  3. This analysis supports the favorable efficacy and safety profile of telmisartan as monotherapy.
  4. Irrespective of the patient’s age, duration, and in mild to moderate hypertension, the study resulted efficacious in the reduction of hypertension.


Dr Tripti Sharma has completed her advanced PG Diploma in Clinical research, Medical and scientific content writing from Cliniminds India. She is an avid medical communicator with versatile experience in the field of medical writing and communication. Also, she has several publications and poster presentations in reputed journals & conferences. Dr. Tripti Sharma is currently associated with USV Private limited as a team member in the Scientific services team.